

IPR & Innovation

1. [MSF urges negotiators to drop harmful provisions from RCEP agreement](#) - Biospectrum

Others

1. ['State testing 2,000 drug samples for quality'](#) – Deccan Herald
2. [Glenmark launches low-price Gliptin for diabetes patients](#) – Business Standard
3. [A healthier India](#) – Business Standard
4. [BDCDA urges DoP to facilitate regulations to raise trade margins of wholesalers & retailers to 10% & 20% respectively](#) - Pharmabiz

IPR & Innovation

1. [MSF urges negotiators to drop harmful provisions from RCEP agreement](#) – Biospectrum

As the trade ministers of the 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) meet in Kuala Lumpur this week to finalize modalities in the deal, Médecins Sans Frontières/Doctors Without Borders (MSF) is calling for the removal of damaging intellectual property provisions in the deal that would risk locking in high drug prices and endangering the health of millions of people across the globe.

To date, nine rounds of negotiations have taken place.

The leaked text of the proposal put forth by Japan and other developed countries includes harmful intellectual property provisions such as patent term extensions, data exclusivity, lowering the bar on patentability criteria, and excessive IP enforcement, all of which extend monopoly protection beyond what is required by existing international agreements.

Others

1. ['State testing 2,000 drug samples for quality'](#) – Deccan Herald

To better promote generic drugs, there is a need to streamline the protocol system, he said. “Ideally speaking, other than the drugs that are imported, the rest should fall under the generic drugs category. However, in India, we presently have branded generics, trade generics and generic-generic category of drugs.”

Subburaj said the Union government’s Jan Aushadhi scheme had not been successful. “Even as drugs are available at one-third the price, there are no takers as there is confusion. Even doctors do not prescribe these drugs. The focus will now be to streamline this,” he added.

2. [Glenmark launches low-price Gliptin for diabetes patients](#) – Business Standard

As part of its effort to expand its footprint as well as revenues in diabetes segment, Mumbai-based generics drug player Glenmark Pharmaceuticals Limited today announced the launch of generic Teneigliptin, a new third-generation oral anti-diabetic drug, at a substantially lower price compared to other Gliptins available in India.

3. [A healthier India](#) – Business Standard

India’s poor health outcomes are well known. Not only have China and Sri Lanka forged far ahead, in recent years Bangladesh and Nepal have overtaken India from behind. As things stand, in South Asia, India remains ahead of only Pakistan. The state of health is a reflection of both what is spent and how it is spent. The twin endeavours must therefore be to sharply increase spending and also

improve governance of health care delivery in both the public and private sectors. In this regard, it is important to note the critical role that publicly funded health care plays in even market-driven economies. Both France and Britain have a higher life expectancy than the United States but spend far less on health as a percentage of gross domestic product (GDP).

4. [BDCDA urges DoP to facilitate regulations to raise trade margins of wholesalers & retailers to 10% & 20% respectively](#) - Pharmabiz

The Bangalore District Chemists and Druggists Association (BDCDA) has urged the department of pharmaceuticals (DoP) to raise the trade margins of wholesalers and retailers to 10 per cent and 20 per cent respectively, based on price to retailer inclusive of excise and added taxes on all formulations.

Incidentally, the DoP had called a meeting with trade and industry regarding trade margins on August 14, 2015 and BDCDA had attended the same.

At the meeting, the Association pointed out to the DoP that in its memorandum via BDCDA/1532 dated July 15, 2013, BDCDA/1893 dated November 26, 2014 and BDCDA/1897 dated December 21, 2014 that all the manufactures and marketing companies were providing the margins exclusive of excise duty.

“We wish to state that in DPCO 2013, margin to wholesalers has to be regulated. The margins to retailers has been fixed at 16 per cent on base rate which amounts to 13.7 per cent on the NLEM. Now as per DPCO 1995, a minimum margin of 16 per cent on MRP was provided to retailers only on scheduled formulations. The manufacturers and marketers were providing margins exclusive of the excise duty,” said V Harikrishnan, president, BDCDA and KCDA.